Eying Clinical Trials, Shattuck Labs Adds $46M for Immunotherapy R&D – Xconomy
Xconomy |
Eying Clinical Trials, Shattuck Labs Adds $46M for Immunotherapy R&D
Xconomy Austin-based Shattuck has an experimental immunotherapy in preclinical development that it believes can fulfill two lofty goals that are currently among the hottest areas of oncology. Its so-called “fusion proteins” aim to combine two approaches to … |
